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ABSTRACT 
Non-small cell lung cancer (NSCLC) is the main subtype of lung cancer (LC) and 
unfortunately it responds very poorly to conventional chemo- and radiotherapy (RT). 
Moreover, NSCLC is often diagnosed at a stage where metastases are found and only for a 
limited number of NSCLC tumors targeted therapies can be used as their oncogenic drivers 
remains elusive. Thus there is a need of finding novel targets in NSCLC and this thesis focus 
around these topics. In Paper I the aim was to find novel RT targets in NSCLC by global 
genomic profiling. It was previously shown that NSCLC cells could be sensitized to RT by 
addition of the staurosporine analogue PKC 412. By global gene expression analyses on this 
NSCLC system we identified the Eph growth factor receptor ligand Ephrin B3 as a putative 
RT target as it was downregulated in the combined RT and PKC 412 treated NSCLC cells. 
Indeed, we demonstrated that Ephrin B3 ablation of NSCLC cells in combination with RT 
increased cellular senescence, mitotic catastrophe and apoptosis, inhibited the cell survival 
kinases Akt, MAPKERK, p38MAPK and decreased RT-induced G2-arrest. Thus we in Paper 
I identified Ephrin B3 as a driver of RT resistance. In Paper II the aim was to investigate 
how Ephrin B3 influences the proliferative “signalome” of NSCLC cells. The 
phosphoproteome of NSCLC cells with or without Ephrin B3 expression was analyzed using 
a peptid-based approach in which SCX and TiO2-based fractionation was used prior to 
identification by mass spectrometry and Ingenuity pathway analyses. Among the 
differentially phosphorylated proteins one candidate was the erythropoietin-producing 
hepatocellular receptor tyrosine kinase class A2 (EphA2), previously shown to control tumor 
cell signaling. We demonstrated that when Ephrin B3 expression was blocked in NSCLC 
cells EphA2 lost its phosphorylation on Ser897, a site previously reported to control 
migration in other tumor types. We also found that inhibition of Ephrin B3 expression 
suppressed Akt1 Ser129 phosphorylation which was reported to control EphA2 at Ser897. 
Thus our findings supported a hypothetical mechanism in which NSCLC cell survival 
signaling was mediated by an Ephrin B3 and EphA2 signaling circuit. In Paper III the 
purpose was to analyze how Ephrin B3 and its putative Ephs mediates their effects on 
migration and invasion of NSCLC of different histology in vitro as well as to reveal as to 
what extent these signaling components may be operative in NSCLC in vivo. Our study 
identified a novel function of Ephrin B3 where it similar to EphA2 controlled proliferation, 
migration and invasion of NSCLC cells in vitro. We showed for the first time that Ephrin B3 
binds EphA2, EphA4, EphA5 and EphA3 indicating a master function of signaling of Ephrin 
B3 in NSCLC. Moreover, as EphA2 Ser897 and Akt Ser129 both were found in complex 
with Ephrin B3 in NSCLC cells and given that we observed p38MAPK and Src kinase in 
such complex our data further add onto how EphA2 may drive NSCLC proliferation and 
migration. In analyses of NSCLC clinical specimen Ephrin B3 was concomitantly expressed 
with EphA2 and its known ligand Ephrin A1 but did not correlate to poor survival. Several 
growth factor receptors, including EphA5, have been shown to control DNA damage 
response (DDR) signaling and hence to constitute RT sensitizing targets. In Paper IV we 
analyzed if EphA2, EphA4 and Ephrin B3 similarly influenced DDR components and hence 
could be used combat RT resistance. Our results showed that a combination of RT and 
ablation of EphA2, EphA4 or Ephrin B3 reduced proliferation and colony forming potential. 
We also described a novel interaction of EphA2, EphA4 and Ephrin B3 with the DDR 
proteins pATM (S1981), pDNA-PKcs (S2056) and γH2AX (S139) suggesting that this 
Ephrin and corresponding Ephs may directly intervene with DDR. Thus this thesis suggests 
that Ephrin B3 and its associated Ephs may be used as novel therapeutic targets in NSCLC 
alone or in combination with RT enabling further progress on precision cancer medicine.     
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1 INTRODUCTION 
Cancer is a devastating disease which may occur in almost all the sites of our bodies. Cancer 
development is the result of multiple signaling aberrations of normal cells enabling  
transformed cells to grow in an uncontrolled way, independently of growth factors and to 
bypass normal cell death control mechanisms, two of the “hallmarks of tumors” as described 
by Hanahan & Weinberg [1, 2]. Moreover, it is evident that establishment of a cancer in a 
human body is a result of the interplay of the tumor cells with the normal surrounding stroma 
and with the immune system, where the tumor cells turn these normal cellular functions into 
their favor, enabling the primary tumor cells to migrate, invade and colonize to other sites in 
the human body, a process called metastasis.  Molecular cancer research, which is the topic of 
the current thesis, aims to understand the underlying mechanisms of such tumor cell 
behaviors in which the knowledge on how to combat such alterations for therapeutic purposes 
is central. With respect to the tumor type in point of the current thesis, non-small cell lung 
cancer (NSCLC), two of the hallmarks of tumors, limited growth potential via aberrant 
growth factor signaling circuits and escape of immune system control have indeed allowed 
for molecular targeted approaches [1, 2]. The current thesis focus onto another growth factor 
receptor family erythropoietin-producing hepatocellular receptor tyrosine kinase (Eph) which 
show aberrant signaling propensity in multiple tumor types including NSCLC. In particular 
this thesis focus onto one of the Eph ligands, Ephrin B3 and how it may enable NSCLC cells 
to proliferate, migrate and invade (Paper I-III). Moreover, this thesis also aims to further 
understand how NSCLC cells respond to radiation therapy (RT) which still is one of the 
major treatment modalities of NSCLC and which in contrast to targeted agents attack 
multiple hallmarks of cancer. In this context the present thesis describes a role of Ephrin B3 
and associated EphAs to control some of these RT-induced signaling events including DNA 
damage response (DDR) and apoptosis (Paper I and IV). On a broader prospective the 
current thesis is aimed to reveal novel therapeutic targets/strategies and biomarkers for 
NSCLC enabling a further improvement of precision medicine approach for this tumor 
malignancy to be taken. 
1.1 LUNG CANCER 
Lung cancer (LC) is a common cancer diagnose which annually is responsible for 1.6 million 
deaths worldwide [3]. In males LC is the primary reason of cancer related death and among 
women it is the second next after breast cancer [4]. In the European Union and United States, 
smoking stands for more than 90 % of LC in men and between 75-85 % LC in women [5]. In 
Sweden, LC is the fourth and fifth most common tumor form among women and men 
respectively [6]. LC incidence differs noticeably due to differences in historical smoking 
patterns, by sex, age, race/ethnicity, socioeconomic status, and by geography [4]. LC has 
traditionally based on cellular morphology been divided into two major subtypes derived 
from epithelial cells, that is Non-small cell lung cancer (NSCLC) and Small-cell lung cancer 
(SCLC) respectively. The present thesis focuses on NSCLC. 
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1.1.1 NSCLC and its treatments 
Non-small cell lung cancer (NSCLC) is the most common form of LC and accounts for 85% 
of all LC diagnosed [7]. Unfortunately in about 65% of all patients, NSCLC is detected at a 
late stage when it is no longer feasible to remove the tumor by surgery [8]. Based on 
histology, NSCLC is further subdivided into adenocarcinoma (50%), squamous cell 
carcinoma (40%) and large cell carcinoma (10%), respectively [9]. Adenocarcinomas usually 
arise in the distal airways and have a glandular histology whereas squamous cell carcinomas 
have as the name indicate, a squamous differentiation, are found in the more proximal, and is 
highly associated with chronic inflammation and smoking [10, 11]. The last histological 
subtype, large cell carcinoma is a description of tumors whose cells neither appears glandular 
or squamous in shape nor expresses their biomarkers [10]. It has been noted that 
adenocarcinomas are increasing in women and in never-, light- and former smokers 
worldwide [12] whereas in current smokers or heavy former smokers squamous cell 
carcinoma are more common [13].  In 2011, a joint working group consisting of oncologists, 
radiologists, molecular biologists, surgical oncologists and pathologists made a new 
histologic classification of NSCLC adenocarcinomas [14]. It was agreed that pathologists 
need to separate classification of these NSCLC based on molecular aberrations found in the 
tumor specimen [15].  The reason for this specification is that certain genetic alterations in the 
NSCLC adenocarcinomas notably mutations in the Epidermal growth factor receptor (EGFR) 
gene or EML4-ALK translocations render these cases amendable to targeted therapy with 
small kinase inhibitors towards either aberration i.e. erlotinib/gefitinib or crizotinib.   Hence, 
by this patients will receive a more individualized cancer treatment. Unfortunately, for most 
NSCLC patients targeted therapy has not yet emerged and given that about 60% of all 
NSCLC patients present with metastatic disease which has a 5-year survival rate of less than 
5% [16] [17] there is a great medical need to find biomarkers and novel therapeutic 
approaches for NSCLC.  
Mutations in EGFR, KRAS, HER2, BRAF and p53 or rearrangements of ALK and ROS1 are 
all found in various subsets of NSCLC tumors [8] where KRAS mutations are more 
frequently found in smokers [18]. In addition MET amplifications and RET rearrangements 
can also be found [19]. Hence, somatic mutations, chromosomal rearrangements and 
alterations in copy number have all been shown to be increased in NSCLC [20].  
EGFR is frequently overexpressed and/or abnormally activated in NSCLC adenocarcinoma 
and a small fraction of this NSCLC subtype also displays mutations in the tyrosine kinase 
domain [21, 22]. Thus, in the USA roughly 10% of patients with NSCLC adenocarcinoma 
and in East Asia 35% of all such cases have a tumor which harbor EGFR mutation. There are 
four common mutations identified in EGFR namely exon 18 and 21 point mutations, exon 19 
deletions and exon 20 insertions [23, 24].  
Around 90% of EGFR mutations which results in a EGFR-driven NSCLC are either deletion 
of exon 19 (ex19del) or L858R point mutations and NSCLC patients with these mutations are 
  3 
responsive to treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) e.g. erlotinib or 
gefitinib [25, 26].   
The T790M point mutation in exon 20 is the most common resistance mechanism to EGFR 
tyrosine kinase inhibitors and can be found in 50-65% of treatment refractory patients that 
previously were found to have an EGFR mutation of their tumor [19]. The T790M mutation 
prevents binding of tyrosine kinase inhibitors to EGFR [27] but can also increase the affinity 
for ATM binding to the kinase, both which lessens the efficacy of tyrosine kinase inhibitor 
blockade [28]. Identification of oncogenic activation by EGFR mutations or ALK (anaplastic 
lymphoma kinase) gene rearrangements has changed the standard treatments towards a more 
molecular targeted approach and genetic analysis for finding the changes in LC is driving 
treatment to personalized cancer medicine [29]. 
LC treatment depends on tumor stage. For stage I and stage II the intention with the treatment 
is curative with first choice being surgical resection of the primary tumor [30]. If surgery is 
not an option, stereotactic body radiotherapy (SBRT) is a different choice with favorable 
survival benefit and acceptable toxicity at least for early stage disease (Stage I) [31]. In stage 
II adjuvant chemotherapy (CT) can be given in which a platinum agent most often is used 
combined with pemetrexed, vinorelbine or gemcitabine [32]. For stage IIIa surgery is 
preferred whenever possible and either followed by adjuvant CT, completely resected or by 
chemoradiotherapy if not. For Stage IIIb chemoradiotherapy is preferred [33]. As for stage IV 
which is an advanced stage of the disease normally palliative therapy is given using CT with 
combinations as mentioned above and in second line docetaxel or paclitaxel, but also targeted 
therapies have emerged such as tyrosine kinase inhibitors against EGFR or ALK [34].  
1.2 RADIATION THERAPY AND MOLECULAR SIGNALING 
Radiotherapy (RT) is used for loco regional tumor treatment of stage III NSCLC and is given 
to about 50% of such patients with curative intent [35, 36]. Albeit RT offer a way to control 
the NSCLC disease at least for some time, two problems with RT is however the intrinsic 
radiation resistance mechanisms of the NSCLC cells but also and the adverse reactions 
coming from irradiation of normal tissue surrounding the tumor [36]. In order to circumvent 
these problems different strategies has been proposed such as radiation protection of the 
normal tissue cells but more importantly, specific radiation sensitizing of the NSCLC cells 
[36]. However, in order to do so it is important to understand the underlying molecular 
mechanisms of the RT resistance such as the targets and cellular pathways that is involved. 
Molecular pathways or targets suggested used for such purpose are: inhibition of cell cycle 
control by blockade of CHK1 or CHK2 (Checkpoint Kinase-1 and -2) activity [36] or CDKs 
(Cyclin-Dependent Kinases) function [37], or blockade of DNA repair by targeting ATM 
(Ataxia-Telangiectasia Mutated) [38] or DNA-PK [39]. In (Paper I and IV) of this thesis 
Ephrin B3, EphA2 and EphA4 are presented as novel molecular targets for RT sensitization. 
Below the physical and molecular aspects of ionizing radiation (IR) is given and putative RT 
resistance pathways of relevance to the current thesis is presented. 
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1.2.1 Basic radiation physical aspects and inflicted cellular damages  
Radiotherapy (RT) which can also be referred to as ionizing radiation (IR) and consists of 
electromagnetic x-rays or γ-rays where the energy of the radiation is deposited in the tissue 
by photons [36]. The term Linear Energy Transfer (LET) describes the energy which IR 
deposit per unit of length it cross and is given as keV/µm [32, 40, 41]. Such energy of 
photons deposited in the matter they cross such as in the cell membrane, cytosol or the DNA 
causes ionizations of the cellular macromolecules and give rise to the damages of which 
damages to the DNA is most detrimental for the cell [32, 40, 41]. 
The main cellular target of IR is the DNA and upon IR, the DNA is passed by an electron or 
an ion and thereby becomes either directly or indirectly ionized.  For conventional RT 
indirect ionizations of DNA is most common and is a result of ionizations of water molecules 
resulting in production of highly reactive hydroxyl radicals that diffuse into the DNA and 
react with the target molecule and cause damages [42]. In addition, reactive oxygen species 
(ROS) and aqueous free radicals such as reactive hydroxyl radicals and H2O2 may also 
produce such lethal damages to the DNA [42]. 
1.2.2 DNA damage response (DDR) signaling in response to RT 
Upon DNA damage, DNA damage response (DDR) signaling networks become activated 
which in turn result in cell cycle arrest in G1 or  G2-phase allowing either DNA repair to take 
place (Figure 1) or different cellular death pathways such as apoptosis, mitotic catastrophe, 
autophagy and senescence to be triggered  (Figure 2) [36]. These different cellular events are 
presented below.  
Ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia and RAD3-related (ATR) are 
the main DDR sensors and these kinases phosphorylate and activate downstream proteins 
upon sensing the DNA damage [43, 44] (Figure 1). 
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Figure 1: IR-induced DNA damage response signaling and downstream DNA repair and cell cycle 
signaling events.  For details see text.  
IR may result in both DNA single- and double strand breaks (DNS SSBs and DNA DSBs 
respectively) with ATM being the master DDR sensor of DNA-DSBs [45] while ATR is 
activated in response to DNA SSBs as a result of stalled replication forks [46]. The 
checkpoint kinase-1 (CHK1) and -2 (CHK2) are the transducers in DDR acting downstream 
of ATM [47] and together with ATM they phosphorylates the tumor suppressor p53 at 
various sites [48]. P53 becomes stabilized in the cell nucleus by such phosphorylation and 
after dissociating from its natural inhibitor Mdm2 (mouse double minute 2 homolog) it can 
act as a transcription factor for genes involved in IR-induced cell cycle block and/or IR-
induced cell death [49]. The stronger the DNA damage level is the more p53 is stabilized [36] 
and depending on if p53 is becoming also altered by other post translational modifications 
e.g. acetylated or methylated, it sets the fate of cell survival or cell death [50].  
One principle action mechanism of p53 is to cause cell cycle arrest by phosphorylation of p21 
(CDKN1A, cyclin-dependent kinase inhibition 1A) which in turn inhibits the cyclin 
dependent kinases CDK4/CDK6 activity with cyclin D and as a result cells are arrested cells 
in G1-phase [50, 53] (Figure 1). p21 also blocks the entry of cells from G2 to M-phase of the 
cell cycle by binding to the CDK1-cyclinB complex [36]. As p53 is mutated in approximately 
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50% of all NSCLC cases [51] and since IR-induced G1 arrest mainly is controlled by the 
p53/p21 axis in such NSCLC cells, IR-induced G2-M control is of major importance since it 
can both carried out independently of p53 [52]. The cell cycle can also be controlled by the 
phosphorylation of CDC25 (cell division cycle 25) isoforms A, B and C by CHK1 and 
CHK2. This results in ubiqutination and degradation of CDC25 [36]. These events results in 
blockage of dephosphorylation and activation of CDK2-cyclin E and CDK1-cyclin B 
arresting cells in G1-phase and in G2-phase of the cell cycle respectively [53] (Figure 1).  
IR-induced DNA DSBs are repaired by either of two principal pathways namely non-
homologous end joining (NHEJ) and homologous recombination (HR) [53] (Figure 1). 
NHEJ can repair DNA DSBs during the whole cell cycle as it can ligate the DSBs without a 
need for a correct DNA template. However, NHEJ is error-prone since it during the repair 
processes may cause short deletions or additions onto the DNA sequences if the DNA ends 
needs processing before ligation can occur resulting in loss of genetic information [54]. On 
the contrary HR is an error free DNA repair pathway, but is only available in late S and G2-
phase since it needs an undamaged sister chromatid as a DNA template. It is the Ku70/Ku80 
heterodimer that senses the DNA DSBs and decides if it is NHEJ or HR that will become 
activated [54]. In addition, the Ku70/Ku80 complex may also activate 53BP1 (p53-binding 
protein 1) which protects the DSB ends against resection [55]. DNA DSB formation also 
results in chromatin alterations and as a result the histones surrounding the break γH2AX 
Ser129 stabilize the DNA ends but also to bring together the DSB repair machinery [56, 57] 
including Artemis and the DNA dependent protein kinase (DNA-PK) [54, 58]. DNA-PK is 
thus an important DNA DSB sensor which in addition to ATM control phosphorylation of 
H2AX [58]. Within NHEJ the DNA ends are then subsequently ligated by LIG4 (DNA ligase 
4), XRCC (X-ray repair, complementing defective, in Chinese hamster 4) and XLF (XRCC4-
like factor) [54].  
In HR it is the MRN complex with MRE11/RAD50/NBS1 that starts the DNA DSB repair 
where the signal is transmitted to ATM and ATR which in turn phosphorylate downstream 
effectors [36]. RPA also bind to the MRN complex and search for homology between the two 
sister chromatids [59]. Moreover, the MRN complex in combination with CTIP (CTBP (C-
terminal binding protein)-interacting protein) also process the DNA ends in the DNA DSB by 
resection [60]. By annealing the established single-stranded DNA to the unwound sister 
chromatid, HR can be initiated. This is done by RAD51 which forms a complex with 
phosphorylated and activated BRCA2 (breast cancer 2) and subsequently RAD51 can bind 
single stranded DNA [61]. The cell cycle will be completed if the DNA DSB has been fully 
repaired while improper DNA repair after IR will start the process of cell death either by 
mitotic catastrophe, apoptosis or senescence as outlined below [62]. 
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1.2.3 Principal cell death signaling routes and RT-induced signaling effects  
IR may induce different cell death routes including apoptosis [63], mitotic catastrophe [64] 
and senescence [65].  
Apoptosis is a cell death mechanism with the characteristics of cell shrinkage, membrane 
blebbing and condensation/fragmentation of the chromatin in addition to formation of 
apoptotic bodies [66]. The molecular path of apoptosis resulting in caspase activation and 
subsequent signaling may be conceived by either of two principal routes, the intrinsic or 
mitochondria mediated pathway or via the extrinsic apoptotic pathway in which death 
receptors such as FASR are instrumental [67] (Figure 2). 
 
Figure 2: IR-induced apoptotic signaling. Ionizing radiation (IR) causes formation of ROS which trigger DDR 
signaling. DDR may activate apoptotic signaling via mitochondria, the apoptosome and caspase-3 resulting in 
apoptotic morphology in which signal via the p53/NOXA/PUMA axis is one path by which the DDR signal is 
transmitted. Apoptosis may also be initiated via Fas/FasL/caspase-8/Bid. IR also activates EGFR/IGF-1R with 
subsequent MAPK/ERK signaling. Such signaling may alter Bad/Bcl-xL function and block apoptosis. 
In the intrinsic apoptosis signaling cascade which is activated in response to IR, release of 
cytochrome c from the mitochondria is important [68] and is controlled by members of the 
BCL2 (B-cell lymphoma 2) family proteins [69]. BCL2 proteins may either be anti-apoptotic 
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where BCL-XL and BCL-2 is operative, or pro-apoptotic where Bak and Bax (BCL2-
associated X protein) as well as the BH3-only proteins Bid, Bim, Bad, PUMA (p53-
upregulated modulator of apoptosis) and NOXA are members [70].  
Upon nuclear accumulation of p53, the pro-apoptotic BCL-2 genes BAX, PUMA and NOXA 
are activated by transcription and may transmit a pro-apoptotic signal onto mitochondria [71-
73]. Subsequently, complex of the pro-apoptotic Bax or Bak and the anti-apoptotic BCL2 
proteins are dissolved resulting in Bak/Bax oligomeric pore formation [71, 74] which may 
cause inner mitochondrial membrane (IMM) permeability transition [75]. The mitochondrial 
protein cytochrome c is released to the cytosol [75] and forms a complex with APAF1 
(apoptotic protease activating factor 1) and pro-caspase-9 [76]. As a result, caspase-9 is 
cleaved and activated [76] and will further activate the effector caspases caspase-3 and -7, 
causing the cleavage of signaling and structural proteins resulting in the above described 
morphological features of apoptosis [77]. In addition Akt is a proliferation and anti-apoptotic 
factor which in response to IR is activated by PDK1 and PDK 2 [36] which in turn are 
activated by the EGFR-ERBB2 heterodimers [78, 79]. 
The extrinsic apoptotic pathway is on the other hand dependent on signaling through death 
receptors (DRs) which belong to the TNFR (tumor necrosis factor receptor) family [80]. 
Here, cell surface DR such as FASR binds to its ligand FasL and as a result a complex is 
formed in which the Fas-associated protein with death domain (FADD) is bringing pro-
caspases together resulting in cleavage and activation [81]. This causes cleavage of pro-
caspase-8 into caspase-8 which may subsequently activate caspase-3 and result in the 
apoptotic morphological characteristics [81].  
The principal pathway of apoptosis activated in response to IR in which DNA DSB or SSB 
repair has been un-successful is the intrinsic route [63, 68, 82, 83]. The complete picture on 
how IR may trigger apoptosis is not clear but one important player is p53 which in response 
to DNA damage activate transcription of Bcl-2 family proteins resulting in the molecular path 
outlined above [63, 68, 82]. In addition, production of free radicals by IR can trigger 
cytochrome c release and may also initiate mitochondrial Ca2+ release which in turn also 
may influence pro-apoptotic responses [84]. 
Mitotic catastrophe is a form of cell death induced as a consequence of dysfunctional cell 
division resulting in micro- or multi nuclei formation [36, 85]. Senescence occurs mainly 
either in the G1 or G2 phase in response to IR where p53 activation results in p21 
accumulation and cell cycle arrest [65]. 
1.2.4 IR resistance signaling networks 
The intrinsic resistance to RT displayed in NSCLC cells is reported to be a result of several 
aberrations such as deregulated growth factor signaling, decreased function of cell death 
signaling pathway and increased DNA-repair. Some of these aspects in light of the current 
thesis are described below.   
  9 
The IGF-1R (Insulin growth factor 1 receptor) is involved in RT resistance in numerous ways 
[86-88]. Thus inhibition of IGF-1R and IR resulted in an increase accumulation of NSCLC 
cells in G2-phase of the cell cycle [88]. Interestingly, IR was shown to directly activate IGF-
1R early after IR [87] and it was reported that such activated IGF-1R may increase binding of 
the NHEJ protein Ku70/Ku80 to DNA and in this way promote DNA repair [87]. Moreover, 
IGF-1R was also shown to activate p38MAPK [87], a MAPK kinase which regulates the 
balance between apoptosis and autophagy [89] and was found to control IR resistance in 
NSCLC cells [90]. Indeed inhibition of IGF-1R with small molecule kinase inhibitor 
disrupted the IGF-1R and p38MAPK complex, inhibited the p38MAPK activity and 
sensitized cells to RT-induced cell death [87]. Similarly it has been reported that upon IR 
EGFR shuttle into the nucleus, increases phosphorylation and activation of DNA-PK and 
promotes DNA repair capacity [78].  
In addition downstream targets of IGF-1R or EGFR such as K-RAS, PI3K and Akt signaling 
pathway are also reported to be involved in RT resistance [91]. Thus inhibition of K-RAS 
was shown to increase the RT sensitivity of NSCLC cells and K-RAS mutations was reported 
to be important for PI3K- and Akt-mediated RT resistance [92]. Moreover, with respect to 
NSCLC cells it has been shown that they often display high phosphorylation of Akt Ser473 
and RT resistance [93]. It was also demonstrated that inhibition of the upstream Akt1 kinase 
PI3K resulted in additive effect when used in combination with IR in part as a result of 
increased apoptotic signaling [93]. Furthermore, targeting either Akt1 or the MAPK ERK1 
also sensitized several NSCLC cell lines to DNA damage induced cell death [94].  
All in all this suggest that growth factor signaling may in multiple ways influence cellular RT 
response and this is also further illustrated in Paper I and Paper IV with respect to Ephrin 
B3, EphA2 and to some extent EphA4 signaling in NSCLC cells. 
1.3 MOLECULAR TARGETING OF GROWTH FACTOR SIGNALING IN NSCLC  
The hallmarks of cancer are described to be self-sufficiency in growth factors, limitless 
replicative potential, anti-apoptotic capacity, neo angiogenesis and ability to invade and 
metastasize [1, 2]. These capabilities of tumor cells are a result of oncogene activation or loss 
of tumor suppressive gene function coming from point mutations, gene amplifications/ 
rearrangements, epigenetic silencing of transcription or loss of heterozygosity respectively 
[95]. Hence it becomes important to find the “driver oncogene” responsible for tumor cell 
proliferation/survival where EGFR, p53, K-RAS, HER2, MYC, MET, ALK and BCL2 is the 
common activated driver oncogenes in NSCLC [96, 97].  
Constitutively active or overexpressed EGFR has been associated with poor prognosis and is 
common in several cancer types [98]. EGFR can activate two major pathways involved in 
tumor cell growth, protein translation, angiogenesis, cell metabolism and invasion [99] 
namely the PI3K/Akt/mTOR and the RAS/RAF/MEK/MAPK pathway [100] (Figure 3). 
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Figure 3: Growth factor receptor signaling in NSCLC. Multiple growth factors (IGF-1R, EGFR, HER2, 
HER3, MET, AXL) are concomitantly activate at the plasma membrane as homo-or heterodimers in NSCLC 
cells. Upon ligand binding the tyrosine kinase domains of these growth factor receptors are phosphorylated and 
they initiate multiple kinase cascades (PI3K/Akt, MAPK/ERK, JAK/STAT, SRC and NFKβ) which promote 
proliferation, migration, invasion and metabolic signaling but blocks apoptosis. The yellow marked kinases are 
those studied in the present thesis. The action points of small kinase inhibitors (erlotinib/gefitinib) and inhibitory 
antibody (cetuximab) is shown. 
Accordingly, blocking EGFR signaling is becoming more and more important. EGFR activity 
can be inhibited by either of two principal ways: by using blocking antibodies e.g. cetuximab 
or panitumab that binds to the EGFR extracellular domain thus inhibiting its dimerization or 
by blocking the intracellular kinase domain of mutated EGFR by using small molecules e.g. 
gefitinib or erlotinib [101]. EGFR expression is known to increase upon RT-induced tissue 
damage and monoclonal antibodies against EGFR are effective when EGFR is overexpressed 
hence rationalizing their use in combination with RT [95]. Thus cetuximab is used together 
with RT for advanced head and neck cancer [102]. Moreover, with respect to NSCLC tumors 
with EGFR activating mutations, the use of EGFR TKIs may lead to a rapid tumor regression 
and is also reported to improve RT sensitivity [24, 95]. However some challenges remains 
such as the activity of nuclear EGFR which may due to its localization, not be targeted by the 
current approaches [103].   
1.4 EPH GROWTH FACTOR RECEPTORS AND THEIR LIGANDS EPHRINS 
Receptor tyrosine kinases are known to function as proto-oncogenes and have a role in 
tumorigenesis. Mutated EGFR is indeed a target in certain NSCLCs, which small molecules 
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have been developed towards [104]. Yet other growth factor signaling circuits should be 
explored as targets and one such potential growth factor signaling circuit is the 
erythropoietin-producing hepatocellular (Eph) receptors and their ligands Ephrins [105] 
which is in focus of the current thesis. 
1.4.1 The Eph and Ephrin signaling network 
The Eph kinases were identified about 30 years ago and today they represent the largest 
transmembrane receptor tyrosine kinase (RTK) family [106]. In normal cells Ephs have been 
demonstrated to influence the cell position, cell migration but also in a pronounced way 
regulate cell-cell interaction [107-110] (Figure 4). Thus Ephs and Ephrins control several 
developmental processes including tissue homeostasis, formation of tissue boundaries, axon 
guidance, remodeling of blood vessels and organ size [123]. 
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Figure 4: The Ephrin and Eph signaling circuit in tumor cells. For details see text.   
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There are 14 Ephs described within the human genome and they are based on sequence 
homology, divided into class A (EphA1-8 and EphA10) and class B receptors (EphB1-4 and 
EphB6) [111]. The extracellular part of the Ephs contains the N-terminal ligand-binding 
domain which has a cysteine-rich region with an EGF-like motif, immunoglobulin-like 
motifs, and two fibronectin type III repeats [106]. The extracellular motif of the principal Eph 
also has a membrane-spanning region and a cytoplasmic region including a juxtamembrane 
region with a tyrosine kinase domain which acts as the active kinase site of the receptor [112, 
113]. However EphA10 and EphB6 do not have kinase activity due to modifications of their 
kinase domain and in addition several of the Ephs have alternative spliced forms that differ 
from the prototypical structure, hence resulting in different functions [114]. 
The eight Eph ligands Ephrins, are divided into two classes based on their structure and 
sequence namely class A or B. The Ephrin A ligands are linked to the membrane via a GPI 
(glycosylphosphatidyl-inositol) anchor containing a signal peptide whereas the Ephrin B 
ligands contain a transmembrane region that spans the entire membrane [105]. The 
nomenclature of the Ephrins and Ephs is based on the fact that it was assumed that Ephrin A 
ligands bind to members of the Eph class A whereas Ephrin B ligands should bind to Eph 
class B [115]. However this is not the case and several promiscuous bindings between 
Ephrins and Ephs of the opposite class such has been identified [105]. One example is the 
binding of Ephrin B1-3 to EphA4 and Ephrin A5 binding to EphB2 and EphB4, the later 
which also interact with Ephrin B2 [105]. However the complete picture of Ephrin and Eph 
interaction pattern remain to be solved as illustrated in the Paper II-III of this thesis. One 
interesting feature of the Eph-Ephrin signaling axis is its bidirectional capacity meaning that 
it causes both a forward and a reverse reaction in the Eph or Ephrin expressing cell 
respectively [116-118] (Figure 4). Thus, upon ligand-receptor interaction the Eph kinase 
domain gets activated through phosphorylation and dimerization. Subsequently this leads to 
the transduction of the typical forward signal in the Eph-expressing cell with a subsequent 
activation of downstream signaling cascades [119]. Additionally, the engagement of Ephrins 
to Eph also triggers signaling in the ligand-bearing cells [106]. For instance, in the 
cytoplasmic region of Ephrin B ligands, phosphorylation of tyrosine residues results in the 
recruitment of signaling effectors and activation of signal transduction cascades [106]. Hence, 
Eph kinase activity triggers forward signals whereas the reverse signaling is in part controlled 
by the Src family kinases [105].   
Another way of regulating Eph activity is via the action of soluble Ephrin As that are released 
from the cell and also can bind Ephs such as Ephrin A1 binding to EphA2 [120]. In addition 
kinase-independent Eph signals and Ephrin-dependent signals can occur [121, 122]. The 
bidirectional signals via Eph/Ephrins may also result in the elimination of adhesive Ephrin-
Eph complexes from sites of cell-cell contact through mechanisms of endocytosis resulting in 
their internalization in either the Eph- or the Ephrin- expressing cell [113]. Such signaling 
results in Eph-repulsive responses between the cells [123]. In addition another mechanism is 
operative in which protease-mediated cleavage of the extracellular domain of Eph or Ephrin 
allows cell separation [124-126]. Yet other mechanisms may stabilize the Eph levels. E-
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cadherin promotes Ephrin A1 and EphA2 to be localized to the epithelial cell junctions [127, 
128] and Ephrin A5 binding to EphA4 is reported to be stabilized by the proteolytic actions 
of the metalloproteinase ADAM19 at neuromuscular junctions [129].  
All in all, a combination of Eph-dependent adhesive or repulsive forces may drive the 
individual cell populations that express different combinations of Ephrins and Ephs, and in 
tumors such may allow oncogenic signaling to be executed [123]. Both Ephrins and Ephs are 
expressed in most tissues with different expression patterns and can be co-expressed in the 
same cells [113]. Recently it was shown that beside the regular in trans signaling where 
Ephrin and Eph are expressed on the opposite cells result in a signal, co-expression of Eph 
and Ephrins on  the same cell can exhibit a signal in lateral cis resulting in inhibition of the 
Eph activation in trans. Interestingly such cis signaling may also be operative in NSCLC cells 
as it was shown that co-expression of Ephrin A3 with EphA2 and EphA3 can inhibit their 
ability to become activated by binding Ephrins in trans [130]. Moreover it was also 
demonstrated that such cis interaction of Ephrin A3 and EphA3 was enhanced by a specific 
EphA3 mutation [130]. 
1.5 EPH AND EPHRIN DYSREGULATION IN CANCER  
Both Ephs and Ephrins are reported to play a role in almost all tumor malignances and in 
breast, glioma, prostate, leukemias, melanomas and LC, Ephrin/Eph signaling has been 
studied in depth [106]. The deregulated expression of Ephs and Ephrins are found in the 
tumor cell per se and in the tumor microenvironment i.e. in the tumor stroma [116, 131]. 
Altered Ephrin and Eph signaling are indeed reported to influence several signaling pathways 
that are involved in tumor cell behavior regulation, e.g. the MAPK/ERK and PI3K/Akt, both 
shared with EGFR and IGF-1R signaling cascades, controlling proliferation, positioning and 
migration capacity [123].  
With respect to NSCLC, Ephrin B3 mRNA expression was reported to be increased in 
NSCLC tumor specimen and was found to be associated with a higher risk of relapse [132]. 
EphA3, EphA2, EphA7 and EphB3 expression were similarly reported to be up-regulated in 
NSCLC [106, 134]. Moreover, NSCLC cell migration and invasion in vitro was shown to be 
prevented by forced overexpression of EphA4 [132] or EphB3 [133]. Not only is Eph 
expression deregulated in NSCLC, global analyses of mutations in the genome of NSCLC 
adenocarcinomas revealed that EphA3 and EphA5 were among the top five most frequently 
mutated genes with mutations found in both the ligand binding as well as in the kinase 
domain of the receptor [135-137]. On the contrary the expression of Ephrins and Ephs can 
also be downregulated in tumors. In metastatic NSCLC cases EphB6 was shown to have 
decreased expression as compared to non-metastatic cases [138]. Moreover, EphB6 
mutations were linked to metastasis in a subset of NSCLC patients [139]. A role of EphA2 in 
cancer in general and in NSCLC in particular is evident and is in focus of this thesis. It will 
therefore be discussed in depth below. 
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1.5.1 EphA2 and tumor cell signaling 
EphA1 was as the first member of Eph family cloned in the late 1980:ies [140] and following 
this EphA2 was identified by screening a cDNA library for sequence homology to EphA1 
[141]. Approximately 25-30% of EphA2 show sequence homology with other Ephs [112]. 
Ephrin A1 is a well described ligand of EphA2 [142] which was found based on its binding to 
the extracellular region of EphA2 [143]. Based on the crystal structure of the extracellular 
domain of EphA2 it has been postulated that a high concentration of the EphA2 clustering 
independent of Ephrin could impart a typical cancerous cell phenotype [144]. Accordingly, 
overexpression of EphA2 has been found in many tumor forms such as in lung 
adenocarcinoma, glioma, breast, colorectal, ovarian and prostate cancer where it is reported 
to drive proliferation and invasion [131, 145-152]. The overexpression of EphA2 has been 
linked to a poor prognosis in several tumors including LC [147]. An EphA2 mutation at 
G391R in NSCLC has also been identified which result in a constitutive active EphA2 that 
trigger activation of Src [153]. Thus, by activating focal adhesions, actin cytoskeletal 
regulatory proteins and mTOR, tumor survival and invasiveness is increased [153].  
In NSCLC a higher EphA2 expression compared to normal non-tumor tissue is reported and 
EphA2 expression correlated to poorer prognosis in addition to a history of smoking [145]. 
Moreover, a high EphA2 expression was found in advanced stage of the disease. In addition, 
patients displaying brain metastasis exhibited high EphA2 levels [145]. Interestingly, in 
embryonic fibroblasts EphA2 were shown to be an important p53-independent and caspase-8-
dependent pro-apoptotic factor [154]. In addition downregulation of Ephrin A1 in breast 
cancer cells was shown to increase EphA2 tumor invasiveness [155]. Moreover, in both 
prostate cancer and glioma cells association of Ephrin A1 and EphA2 was reported to inhibit 
EphA2 Ser897 as well as Akt Ser129 phosphorylation resulting in inhibition of proliferation- 
and invasion signaling mediated by EphA2 [150, 156]. However, the results regarding EphA2 
phosphorylation status and tumor malignancy are contradictory and suggest that certain sites 
indeed may block EphA2 growth and invasion controlling capacity [146, 157-160]. Thus it 
was reported that NSCLC treatment with an Ephrin A1-Fc resulted in a transient increase of 
EphA2 phosphorylation contributing to a decrease of total EphA2 expression due to rapid 
internalization and degradation [146].  
In prostate and breast cancer EphA2 phosphorylation was shown to be necessary to confer the 
oncogenic potential of EphA2 [157-159]. Moreover other studies suggest that EphA2 
phosphorylation is not needed in order to impart tumorigenicity [128, 160] or that EphA2 
phosphorylation causes tumor suppression [161]. When screening the literature it becomes 
evident that the function of EphA2 depends on the conditions and available ligands as 
illustrated in Paper III of the current thesis. For instance EphA2 activation was reported to 
inhibit chemotactic migration of glioma and prostate cancer cells upon interaction with 
Ephrin A1 whereas overexpression of EphA2 triggered migration in a Ephrin A1 independent 
manner [150]. In NSCLC stage I higher expression of EphA2 and Ephrin A1 was shown to 
correlate to good clinicopathological features [162]. Thereby indicating that in presence of 
Ephrin A1, EphA2 has a tumor suppressive role [162]. 
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1.5.2 EphA2 as a therapeutic target 
Several tyrosine kinase receptors have been targeted for their critical roles in tumorigenesis 
[163] and an interest in EphA2 as a therapeutic target has emerged since EphA2 is 
overexpressed in various cancers while expressed at rather low levels in normal cells. EphA2 
has indeed been evaluated as a drug target using several approaches such as RNA 
interference (RNAi), Ephrin A1 mimicking agonistic antibodies, virus vector-mediated gene 
transfer that target deregulated Ephrin A1 and EphA2 signaling in tumor cells, 
immunoconjugate approaches but also small-molecule inhibitors which block kinase domain 
and nanoparticles loaded with CT and with EphA2 as targeting moiety [164].  
Monoclonal antibodies have been designed against the extracellular domain of EphA2 [165]. 
Indeed treatment with these EphA2 agonist monoclonal antibodies alone or in combination 
with the mitosis inhibitor paclitaxel was reported to reduce tumor growth in mice, and it is 
believed this is a result of EphA2 internalization and degradation causing inhibition of the 
Ras/MAPK pathway [164]. Hence, monoclonal antibodies specific to EphA2 could function 
similarly as Ephrin A1 and reduce the oncogenic potential [164]. By using monoclonal 
antibodies to deliver CT agents, immunoconjugates will induce cytotoxicity in tumor cells 
and it is believed that since EphA2 is less expressed in normal than in tumor cells, the normal 
cells will be spared [164]. Immunotherapy is also a way to target EphA2 since epitopes on 
EphA2 are differentially displayed in cancer versus normal cells [166]. In breast- and NSCLC 
cells some EphA2 antibodies is reported to react strongly but not to normal immortalized 
breast cells indicating that EphA2 epitopes indeed can be used as therapeutic targets [164]. 
In prostate cancer cells, a small molecule against EphA2 inhibited EphA2 phosphorylation 
[164]. In addition dasatinib which is an FDA approved small-molecule tyrosine kinase 
inhibitor was shown to prevent EphA2 activity [167] and to cause decreased expression of 
EphA2 in breast cancer cells [168]. RNA interference (RNAi) approaches have also been 
used in order to suppress EphA2 overexpression. Hence EphA2 expression was inhibited by 
RNAi in pancreatic adenocarcinoma-derived MIA PaCA2 cells and blocked tumor growth in 
a nude mice xenograft model concomitantly with increased apoptotic signaling [169]. 
Inhibition of EphA2 in human glioma-derived U-251 cells was similarly reported to increase 
caspase-3 activity and apoptosis in addition to a reduction in tumor cell proliferation [170]. 
Suppression of EphA2 by siRNA in malignant mesothelioma derived cells decreased cell 
proliferation and downregulated migration as EphA2 overexpression increased cell 
proliferation [173]. Moreover siRNA against EphA2 in human glioma cells induced 
apoptosis and inhibited proliferation [170]. 
EGF or EGFR signaling has also been reported to regulate EphA2 activity and expression in 
NSCLC [145] and in head and neck carcinoma-derived cell lines [171, 172]. EphA2 
suppression in such cells decreased EGF-induced migration indicating that there is a cross-
talk between EGFR and EphA2 signaling that could be used for therapeutic purposes [171, 
172]. Recently it was also shown that a small molecule against the EphA2 kinase domain 
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could revert erlotinib resistance in vivo in mice in which a decreased EphA2 expression level 
was evident [213, 214].  
All in all these studies indicate that EphA2 inhibition is a feasible approach for targeting 
different tumors including NSCLC. Moreover, inhibition of EphA2 in combination with 
targeting of other oncogenic signaling molecules e.g. mutated EGFR is thus an important 
strategy for targeted cancer therapies approaches. 
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2 AIMS 
The overall aim of this thesis was to analyze mechanisms of Ephrin ligand and Eph receptor 
signaling in NSCLC cells alone or in combination with radiotherapy (RT). The specific aims 
of the PhD project were: 
 To reveal novel RT sensitizing targets in NSCLC cells by using global gene 
expression profiling and to validate Ephrin B3 as such novel candidate (Paper I). 
 
 To understand how Ephrin B3 influences the proliferative signalome of NSCLC cells 
by application of a global phosphoproteomic profiling and subsequent validation of 
signaling components (Paper II). 
 
 To reveal if and how Ephrin B3 mediate effects on NSCLC cell migration and 
invasion and delineate putative Ephs such as EphA2 involved in its action mechanism 
in vitro and in vivo (Paper III).  
 
 To address the impact of EphA2, EphA4 and Ephrin B3 on RT sensitivity in NSCLC 
cells and analyze their effect on DDR (DNA Damage Response) signaling 
components DNA-PK and ATM (Paper IV).   
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3 MATERIAL AND METHODS 
For Paper I-IV all corresponding material and methods are described in brief below. 
3.1 CELL LINES AND MODEL SYSTEMS 
To cover the different histological subtypes that NSCLC is classified into, a panel of NSCLC 
cell lines of adenocarcinoma, mixed large cell/adenocarcinoma, squamous cell carcinoma and 
adenosquamous cell carcinoma origin was used (Paper I-IV). The cell lines alongside their 
histology, radiosensitivity, mutation status of Eph and K-Ras are presented in Table 1. The 
intrinsic radiotherapy sensitivity of the cell lines measured as surviving fraction 2 Gray (SF2) 
in colony formation assay has been published [174-177] and these values were used in Paper 
IV to correlate basal Ephrin B3, Ephrin A1, EphA2 or EphA4 expression to RT sensitivity. 
Clonogenic survival assay is commonly used to describe the RT sensitivity of a given cell 
line and is most often described as survival fraction 2 Gray (SF2). In a clonogenic survival 
assay the potential of the cells to form clones is described as a function of a given radiation. 
Thus the surviving fraction 2 Gy is the amount of cells that survive after being irradiated with 
the dose 2 Gy. An SF2 0.8 means that 80% of the cells treated with 2 Gy still had their 
clonogenic capacity and SF2 1.0 means that all of the cells has survived. The surviving 
fraction of each absorbed dose is calculated as the ratio of the mean PE (plating efficiency) of 
irradiated cells over the PE in dishes with non-irradiated cells used as control [40]. In Paper 
IV cells were allowed to form colonies for 9 days in order to be able to measure reproductive 
cell death. The colonies were subsequently stained with Giemsa and the total colony 
number/dish was counted. 
 
Table 1. Histology, SF2 values and mutation status of the cell lines used. 
 Abbreviations: SF2 = surviving fraction 2 Gray, SNP = single nucleutide polymorphism 
 
https://cansar.icr.ac.uk/cansar/cell-lines/A549/mutations/ 
 http://www.broadinstitute.org/ccle/home  
 
The mixed large cell and adenocarcinoma U-1810 cell line has been used as a model system 
in all the papers of this thesis. Berg et al., at the department of Oncology at Uppsala 
Academic hospital in Sweden isolated the U-1810 cells from a patient with undifferentiated 
large cell carcinoma/adenocarcinoma and hence the ``U´´ stands for Uppsala. Similarly the 
Histology Cell line Mutation status/Variant type SF2 
H23 EPHA6/Insertion, KRAS/SNP 0.2
H1299 EPHA6/Insertion, EPHA7/SNP 0.3
Adenocarcinoma H157 0.6
A549 EPHA1/SNP, EPHA6/Insertion, EPHB6/Deletion, KRAS/SNP 0.7
H661 EPHA6/SNP,Insertion 0.9
Adensquamous cell carcinoma H125 0.4
Squamous cell carcinoma U-1752 0.9
Mixed large cell and adenocarcinoma U-1810 0.8
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U-1752 cell line was also a kind gift from Uppsala University whereas the rest of the cell 
lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). 
With respect to radiation, the U-1810 cell line has over the years been extensively studied and 
found to be highly radiation resistant [94, 178, 179]. Moreover, it was previously 
demonstrated that U-1810 cells could be sensitized to RT by the staurosporin analogue 
PKC412 in part as a result of increased pro-apoptotic signaling but also as a consequence of 
mitotic catastrophe [94, 178]. In Paper I and IV this cell line was therefore chosen as a 
model system to reveal drivers of RT resistance and to understand Ephrin B3 and EphA2, 
EphA4 and EphA5 in this context. In Paper II, U-1810 was used to further investigate the 
signaling pathways driven by Ephrin B3 and in Paper III it was chosen alongside U-1752 
and H23 to get a deeper understanding of the role of EphA2 and Ephrin B3 in pro-survival 
signaling, proliferation and migration in relation to histology. 
In order to analyze if inhibition of Ephrin B3 or EphA2 expression could decrease invasive 
capacity of NSCLC cells (Paper III) CL1-5 adenocarcinoma cells, with high invasive 
potential, kindly given by Dr Pan-Chyr Yang (Institute of Biomedical Sciences, Academina 
Sinica, Taiwan) was used. The CL1-5 cells have been generated from adenocarcinoma CL1-0 
cells by selecting for clones with increased invasion potential in transwell invasion chamber 
assay [180,181]. 
3.2 IRRADIATION 
In Paper I and Paper IV conventional radiation was delivered as photons of gamma rays 
using a 
60
CO source (absorbed dose 2 Gy, 4 Gy or 8 Gy) with the monthly dose rate 
<0.5Gy/min determined according to decay of the source. In Paper IV for some experiments 
irradiation was carried out on ice in order to inhibit DNA DSB repair during the irradiation 
procedure while all other IR procedures was carried out at room temperature. 
 
3.3 RNA INTERFERENCE 
In Paper I-IV short interference RNA (siRNA) was used to block expression of Ephrin B3, 
EphA2 or EphA4. A siRNA consists of short double stranded RNA with 20-22 nucleotides 
which upon cleavage in the cell bind to specific sequences of mRNA and after transcription 
results in mRNA digestion and subsequently inhibition of mRNA expression [182]. The 
challenges with this method are that for each single siRNA in each model system the 
experimental conditions (e.g. transfection time and amount of siRNA) need to be optimized 
in order to have a good knockout of the target gene. In addition off-target effects resulting in 
non-specific RNA degradation by the siRNA remains a challenge as it may blur the 
interpretation of results. To avoid this, a non-targeted siRNA which was designed and tested 
for minimal targeting of different genes was applied in Paper I-IV.  
The siRNA of Ephrin B3 (Qiagen, Maryland, USA) applied in Paper I-IV was custom made 
and previously described to be unique towards Ephrin B3 [183]. In addition, in Paper I a 
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second Ephrin B3 sequences was used to confirm the results [183]. For siRNA targeting of 
EphA2 in Paper II-IV and EphA4 in Paper IV four different sequences was used to improve 
on both efficiency and specificity of the siRNA towards its target. In all experiments 
approximately 500 000 cells were seeded in 10 cm dishes followed by siRNA transfection 
using 100nM siRNA. Cells were seeded 24h prior to siRNA transfections which were carried 
out for 24h-48h with different post incubation times. Knock-down was confirmed by western 
blot or Real-time quantitative PCR as describe in section 3.4. 
3.4 CELL BASED ASSAYS 
To assess the different outcomes of NSCLC cells in response to EphrinB3, EphA2 and 
EphA4 siRNA and/or irradiation treatments different cell based assays was used and are 
described in brief alongside their rationale below. 
3.4.1  Analysis of proliferation and cell death 
Apoptotic morphology of the cell nuclei was in Paper I analyzed by staining the nuclei with 
mounting media containing 4,6´diamino-2phenylindole (DAPI) and examined in a 
fluorescent microscope. Cells were determined to be apoptotic if a fragmented nuclei was 
evident and the number of such cells was counted. Apoptosis was also biochemically 
examined in Paper I by analyzing cytokeratin 18 cleavage by caspase 3 using an antibody, 
M30, which specifically recognize this caspase-released neo epitope of cytokeratin 18. By 
using Fluorescence Associated Cell Sorting (FACS) the percentage of cells with M30 
CytoDeath-FITC antibody (Roche Diagnostics Scandinavia AB, Stockholm, Sweden) 
positivity was detected. In addition analysis of PARP-cleavage as a result of caspase-3 
activity was analyzed by western blotting as a way to demonstrate apoptosis in Paper I.   
In Paper I, Senescence Cells Histochemical Staining Kit based on the X-gal staining of cells 
was used and the percentage of β-galactosidase expressing cells was observed in a light 
microscope. Briefly, in senescent cells β-galactosidase catalyzes the hydrolysis of β-
galactosides into monosaccharides and gives them a distinct blue color. 
In Paper I, cell division was analyzed by carboxyfluorescein succinimidyl ester (CFSE) 
staining and subsequent analyses by FACS as described by Quah et al. [184]. CFSE is a cell-
permeable agent which labels long-lived intracellular molecules with a carboxyfluorescein 
which is a fluorescent dye. Hence, when cell division occurs, the progeny of the CFSE-
labeled cell are endowed with half of the carboxyfluorescein-tagged molecules [184].  
MTS proliferation assay (CellTiter 96 AQueous non-radioactive cell proliferation Assay 
(Promega, SDS, Falkenberg, Sweden)) was used in Paper I as an additional cellular 
proliferation assay. The MTS assay labels cells with a salt that in viable cells with functional 
mitochondria is converted to formazan crystals [185]. The resulting formazon crystals are 
dissolved in a SDS-containing buffer and their absorbance measured at 595 nm in a 
spectrophotometer is proportional to the number of viable cells.  
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In Paper III and Paper IV proliferation post siRNA treatment alone or in combination with 
IR was also examined by manual counting of trypan blue positive and negative cells in 
Bürken chambers. 
3.4.2 Cellular fractionation and immunoprecipitation 
In Paper IV the expression level of Ephrin B3 to EphA2, EphA4 and EphA5 and the 
phosphorylation of the DDR components pDNA-PKcs (S2056), pATM (S1981) and γH2AX 
(S139) were analyzed in  plasma membrane and cell nucleus fractions pre and post IR of 
NSCLC cells. For that purpose cell extracts were fractionated by using the Qproteome cell 
compartment kit (#37502, Qiagen, Germany) and analyzed by western blot. The western blot 
membranes were probed with Caveolin-1 and Histone H3 to reveal membrane or nuclear 
fraction purity respectively.  
In order to determine the binding partners of Ephrin B3, immunoprecipitation was carried out 
in Paper II-III. In Paper II a Pierce Direct IP kit (prod #26148 Pierce/Thermo) was used 
according to manufacturers´ instructions with the modification that UREA buffer (6M urea 
and 2% SDS in 200mM Ammonuimbicarbonate and proteases inhibitors (Roche, Mannheim, 
Germany)) was used instead of elution buffer. The reason for the modulation in the protocol 
was that the samples by this approach also could be used for masspectrometry later on. In 
Paper III 800µg of total cell lysates of U-1810, H23 or U-1752 cells was lysed in buffer (25 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 and 5% 
glycerol).Protein G-Sepharose beads (Millipore) was used in order to fish out the 
immunoprecipitation conjugates and IgG (#12370, Millipore) was applied as a negative 
control. The immunocomplexes and input was both in Paper II-III loaded onto a gel for 
western blot analysis. 
3.4.3 Proximity ligation assay 
Proximity ligation assay (PLA) offers a way to study protein-protein interaction [186]. In 
PLA, two primary antibodies from different species that recognize the antigens of interest are 
applied followed by secondary antibodies conjugated with PLA probes specific for each of 
the primary antibodies. Throughout ligation, where oligonucleotides and ligase are added, 
hybridization of the two PLA probes will start and they will join if the antibodies have bound 
in close proximity. The amplification part with fluorescently labeled oligonucleotides and 
polymerase acts as a rolling-cirle amplification (RCA), generating repeated sequences as a 
products, that can be detected as a fluorescent spots under the microscope [186]. In Paper 
IV, this method was used in order to analyze the interaction of Ephrin B3 with EphA2, 
EphA4, EphA5, DNA-PKcs (S2056), pATM (S1981) and γH2AX (S139). PLA probes were 
obtained with the Duolink II assay kit (OlinkBioscience, Uppsala, Sweden), DAPI (Sigma 
Aldrich) in the mounting medium stained the cell nucleus and an epiflourescent microscope 
Axioplan 2, Zeiss) with a 100-W mercury lamp, a CCD camera (C474∆95, Hamamatsu) and 
emission filters was used for visualization of DAPI (to reveal cell nucleus) and Texas Red (to 
examine PLA probe labelling) respectively. 
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3.4.4 Immunoblotting and Real-time quantitative PCR 
Western blot (WB) and Quantitative real-time PCR (RT-QPCR) was used as analytical 
methods in Paper I-IV for protein/RNA analysis respectively and was also used to validate 
siRNA efficiency. In Paper I-II proteins were extracted using UREA buffer (6M urea and 
2% SDS in 200mM Ammonuimbicarbonate and proteases inhibitors whereas in Paper III-
IV proteins were extracted using RIPA buffer ((50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
0.5% Igepal, 5 mM EDTA (pH 8.0), 0.1% SDS supplemented with PMSF (1 mM) and 
proteases inhibitors. For all experiments in Paper I-IV sonication resolved membrane 
proteins. To determine protein concentration, bicinchoninic acid (BCA) assay (Interchim, 
MontiuconCedex, France) was used. For smaller proteins (>90kDa) 4-12% Bis-Tris gels was 
chosen for separation whereas for larger proteins (<90kDa) 3-8% Tris-Acetate NuPAGE® 
gels (Invitrogen AB, Stockholm, Sweden) was applied.  
For RTQ-PCR, total RNA was extracted by Qiagen RNeasy kit (Sollentuna, Sweden) and 
reversed transcribed (1µg) to cDNA (2.5 μM random hexamer primers, 2 mM dNTPs, 5.5 
mM MgCl, 8 U RNAse Inhibitor, 25 U MultiScribe Reverse Transcriptase in reverse 
transcription buffer (Applied Biosystems)) with heating for 25°C, 10 min, 37°C, 1 h and 
extension at 95°C for 5 min. 1µl cDNA was mixed with Taqman Fast Advanced Master Mix 
and primers for EphA2 or EphrinB3, respectively. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as internal control. Relative expression values were 
calculated using the 2
-∆CT
 formula and analyses were carried out on ABI Prism 7900HT 
Sequence detection system (applied Biosystems). 
3.4.5 Clonogenic survival assay 
The rationale for clonogenic survival assay is given in section 3.1 and was used in Paper IV 
to examine the difference in clonogenic capacity of Ephrin B3, EphA2 and EphA4 expressing 
versus non-expressing NSCLC cells in combination with irradiation. NSCLC U-1810 cells 
were seeded as monolayers and at a confluency of 70-80% transfected with non-targeted or 
the specific siRNA for 24h. Cells were thereafter either mock-irradiated or irradiated with 4 
Gy. At this point cells were counted and 5,000 cells was seeded in 10 cm dishes and allowed 
to form colonies over 9 days. The clones in the dishes were thereafter stained with Giemsa 
and quantified with the cell survival relative to Non-target siRNA and irradiated cells 
determined. 
3.4.6 Migration and invasion assay 
To measure migration and invasion of tumor cells transwell assay is commonly used [187] 
and was applied in Paper III for that purpose. Thus for migration a transwell insert 
(Transwell: Millipore, cat.no PIEP15R48, MA) containing a porous filter were applied on 
which the cells either transfected with non-targeted or Ephrin B3/EphA2 siRNA were 
applied. In order to synchronize the cell cycle and make the cells more prone to migrate 
towards the serum, cells were serum starved for 24 h prior to the assessment. The principle of 
the transwell assay is that cells which have migration capacity will move towards the media 
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containing serum in the bottom of the insert which act as a chemoattractant and the cells will 
end up on the bottom of the filter side. The resulting cells on the membrane were fixed in 
2.5% glutaraldehyde solution and visualized by staining with 0.5% crystal violet solution and 
counted by light microscope. In order to examine the invasion potential of NSCLC CL1-5 
cells with or without Ephrin B3 or EphA2 expression, a modified version of the transwell 
assay was applied in which the insert was covered with growth factor-reduced matrigel (2µg, 
Becton Dickinson). The concept behind this assay is that invasive cells will degrade the 
matrigel and move towards the bottom of the insert. Cells ending up on the filter was 
similarly fixed and stained and quantified as for the migration assay. 
3.5 OMIC BASED ANALYSIS AND BIOINFORMATICS 
Two omics based methods were chosen to explore radiation therapy sensitizing strategies 
(Paper I) and proliferative signaling in response to Ephrin B3 blockade in NSCLC cells 
(Paper II) respectively. These two methods and the principle steps are described in brief 
below.  
3.5.1 Gene array analysis to identify RT sensitizing targets 
In Paper I Affymetrix-based gene array on the Affymetrix plattform (Affymetrix Inc, CA, 
USA) was used to identify differentially expressed genes in NSCLC U-1810 cells after 
treatment with either of the two staurosporine analogues PKC412 or Ro 31-8220 alone or in 
combination with RT. PKC412 was previously reported to confer RT sensitivity in NSCLC 
while the opposite was evident for Ro 31-8220 [94, 178].  For the gene expression profiling 
Affymetrix U133 2.0 plus GeneChip was used on three biological replicates of NSCLC U-
1810 cells treated irradiated with 8 Gy and at 24 h post irradiation pulsed for 4 h with either 
PKC412 or Ro 31-8220. Using RNeasy Mini kit (RNeasy Midi Handbook, Qiagen, KEBO 
Lab Sweden) according to the manufacturers´ instructions, mRNA of untreated or treated 
with PKC412 or Ro 31-8220 and/or irradiated U-1810 cells was isolated. cDNA and cRNA 
synthesis, labeling and hybridization was made in a reaction where cRNA also was biotin-
labelled using the In-Vitro Transcription (IVT) kit (Affymetrix Inc). A streptavidin 
phycoerythrin conjugate was used for the probe hybridization followed by amplification with 
a biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, CA, USA) to 
which a PE-conjugate linked with streptavidin was hybridized. The fluorescent signals from 
hybridized probes on the chip were imaged by scanning the chip on a fluorometric scanner 
(Affymetrix Scanner). The obtained data were processed using GeneSpring GX software 
(AgilentTechnologies) in which the probes for the different gene transcript were summarized. 
To normalize the gene expression two different methods were used. First the gene expression 
on each chip was normalized to allow for differences in labelling of the probes by dividing 
each individual gene of the chip with the 50th percentile of all signals from all probes on that 
chip. In the next step each gene were normalized against all its values in the different samples 
in the biological replicate by taking its median expression level across the treatments. These 
normalized genes were annotated to their different treatments i.e. untreated, PKC412, Ro 31-
8220, IR, IR+PKC412 or IR+Ro 31-8220 and ANOVA (parametric test, variances assumed 
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equal) was used to compare the individual genes in each biological replicate to generate list 
of significantly up or down regulated genes in IR+PKC 412 vs IR+Ro-318220. By RT-QPCR 
the expression pattern of some selected genes from the gene array was confirmed. 
3.5.2 Phosphoproteomic profiling of Ephrin B3-driven signaling 
Phosphorylated peptides are less abundant compared to non-phosphorylated ones and are also 
because of the poor ioniziation of the phosphopeptide in the MS (mass spectrometry) difficult 
to analyze in complex cellular sample. Enrichment methods for the phosphpeptides are 
therefore required. In Paper II, phosphorylated peptides from NSCLC U-1810 cells treated 
with either non-targeting siRNA or siRNA targeting Ephrin B3 were therefore enriched in 
two different ways. First Strong cation exchange (SCX) chromatography was used in which 
the SCX column was linked to an Agilent 1200 LC system. In SCX peptides are fractionated 
based on their net charges where peptides with low positive net charge elute earlier [188]. In 
order to capture as many peptides as possible in each of the samples, the sample was run 
three times on SCX, peptides eluted into 12 different fractions and identical fractionation 
numbers were pooled. Next each of the pooled fractions was subjected to enrichment for 
phospho-peptides in which TiO2 magnetic beads (Mag SepharoseTM, GE Healthcare) were 
used. The principle for enrichment is that the negative phosphate groups on the 
phosphorylated peptide will bind to the positive titanium charges on the beads while non 
phosphorylated peptides will not [189, 190]. The peptides that were bound to the beads were 
after washing eluted in Amonia-based basic buffer (pH>11). In the last step, each sample 
from the 12 fractions enriched for phosphopeptides was injected into online HPLC-MS 
performed on a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo) to reveal their 
corresponding MS spectra. Obtained MS spectra were searched against the Mascot2.2 
(Matrix ScienceLimited, London, U.K.) and peptides with annotation of 95% confidence got 
their MS spectra transferred into Protein center (PROXEON, Thermo Fisher Scientific) in 
which the phosphorylated sites of the peptides in the different samples were compared and 
visualized. These analyses generated a list of protein identities corresponding to the 
phosphopeptides identified in the three MS replicates analyzed. In order to sort out relevant 
signaling events and generate hypothesis from the achieved phosphoproteomic data in 
relation to Ephrin B3 siRNA blockade in NSCLC cells, the Ingenuity Pathway Analysis 
software (IPA) (Ingenuity Systems, Inc., RedwoodCity, CA) was applied. For the IPA 
analyses protein identities from either treatment were loaded into the software which is based 
on public and manually curated data and IPA sorted the data into putative signaling networks 
and processes. From these analyses hypotheses were generated and candidate proteins were 
thereafter manually evaluated in Protein Center (PROXEON, Thermo Fisher Scientific) for 
their differential phosphorylation. Validation of the information and hypothesis obtained was 
done by using siRNA, immunoprecipitation and western blot. 
3.6 ANALYSIS OF CLINICAL LC MATERIAL 
A cohort of 104 NSCLC cases where 92 specimens contained sufficient material, were used 
in Paper III to evaluate Ephrin B3, EphA2 and Ephrin A1 expression. The complete 
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information on the clinical parameters of the NSCLC cases is given in Paper III but is 
described in brief below. Tumor tissues were obtained from patients operated with curative 
resection of the tumor at the Department of Cardiothoracic Surgery, Karolinska Hospital, 
Stockholm, Sweden, between 1988 and 1992. The patient cohort consisted of 43 cases of 
adenocarcinoma and 49 cases of squamous cell carcinoma. No CT or RT was administered 
prior to surgery. The tumors used were formalin-fixed and paraffin embedded (FFPE) and a 
tissue micro array (TMA) was constructed. Slides from this TMA was used and stained with 
Ephrin B3, Ephrin A1 or EphA2 antibodies. This was followed by incubating the slides with 
a biotinylated-conjugated secondary antibody and an avidin-biotin-linked peroxidase 
substrate. A trained pathologist blinded to the study performed a semi quantitative scoring of 
the immunohistochemistry staining of the specimen where the intensity of immunopositivity 
was ranked from low score 1 to high score 2-3. The study was ethically approved by the 
Karolinska Institutet ethical committee (2005/588-31/4). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death 
response of non-small cell lung carcinoma cells after combined treatment with ionizing 
radiation and PKC 412.  
Intrinsic and acquired resistance impedes the clinical use of RT in treatment of NSCLC. It 
has previously been shown that adding the PKC inhibitor and staurosporine analogue 
PKC412 but not Ro 31-8220 sensitized RT resistant NSCLC cells to treatment and that this 
combination increased apoptotic- and mitotic catastrophe signaling [94, 178].  
In this study, we aimed to find novel RT sensitizing targets in NSCLC by using global gene 
expression profiling. We confirmed previous results [94, 178] and showed that a combination 
of PKC412 and IR resulted in decreased proliferation but also increased apoptotic signaling 
via a caspase-3-mediated route. In search for putative targets involved in the sensitization of 
NSCLC cells to RT by PKC 412, a total gene expression profiling was carried out by 
Affymetrix gene array. By analyzing genes that showed a 1.5-fold altered expression in the 
combined treatments of IR and PKC412 or Ro 31-8220, a total of 140 or 179 genes were 
found to be up-regulated and 253 or 425 genes were down-regulated by either treatment 
respectively. Some of these genes were, based on public domain data reporting on their 
relevance to tumor cell signaling in general, selected for validation.  
The Eph receptor ligand Ephrin B3 was a gene found to be down-regulated and was validated 
by RTQ-PCR. A role of Ephrin B3 in IR-induced cellular response and cell death remained at 
this point elusive but given the described role of Eph signaling in tumors [117] we focused 
onto Ephrin B3 as a RT sensitizing target. By blocking Ephrin B3 expression using siRNA in 
combination with IR, NSCLC cells were sensitized to IR as revealed by altered cellular 
morphology, decreased proliferation and increased apoptosis. It was previously shown that 
adding PKC412 on top of RT in NSCLC cells may increase cells which commits mitotic 
catastrophe [94], a form of cell death executed in response of incorrect entry of cells into 
mitosis [191]. Inhibition of Ephrin B3 expression followed by IR indeed increased mitotic 
catastrophe. Senescence is characterized by a decreased cellular proliferation, elongated 
phenotype and an increase in cell size [192]. Such cellular morphology was also observed 
when combining Ephrin B3 silencing with IR in NSCLC cells. Moreover, quantification of 
the number of cells with β-galactosidase positivity showed increased number upon ablation of 
Ephrin B3 expression and IR. It has been reported that p27
kip1
 expression is highest in the G0 
cell cycle phase [193] and in addition to p21
WAF1/Cip1 
and p16
INK4a
 [194] p27
kip1
 is a known 
biomarker of senescence. Analyses of cell cycle progression by flow cytometry and 
proliferative signaling by western blotting showed that Ephrin B3 suppression in combination 
with IR decreased IR-induced G2 arrest and upregulated p27
kip1
 expression. However, both 
p21
WAF1/Cip1 
and p16
INK4a
 showed a decreased expression in NSCLC cells where Ephrin B3 
blockade was combined with RT. Thus our results suggested that neither p21
WAF1/Cip1 
nor 
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p16
INK4a
 were responsible for the cell cycle or induction of senescence that was observed 
upon Ephrin B3 inhibition alone or in combination with IR. Instead obtained results pointed 
towards a function of p27
kip1
in the recorded effect on either process.  
In NSCLC cells with inhibited Ephrin B3 expression phosphorylation of pAkt (Ser473), pP38 
(Thr180/Tyr182) and pERK (Thr202/Thr204) was decreased whereas Ephrin B3 inhibition 
followed by IR did not alter pERK (Thr202/Thr204) phosphorylation. Eph signaling is 
known to influence cellular proliferation by altering MAPKs and PI3K/Akt phosphorylation 
[116, 123] and here we showed for the first time that the Eph ligand Ephrin B3 also is 
involved in such signaling in NSCLC cells. In summary, we identified Ephrin B3 as a 
putative driver of RT resistance involving both altered proliferation-and cell death signaling 
as illustrated in Figure 5. 
 
Figure 5: Summary of findings in Paper I.  
4.2 PAPER II 
Phosphoproteomic profiling of NSCLC cells reveals that Ephrin B3 regulates pro-survival 
signaling through Akt1-mediated phosphorylation of the EphA2 receptor.  
In Paper I we identified Ephrin B3 as a RT sensitizer and driver of NSCLC cell survival. In 
Paper II the aim was to reveal signaling networks that Ephrin B3 utilizes to regulate NSCLC 
proliferative capacity. An unsupervised, global, “bottom up” phosphoproteomic approach 
was taken in which changes in phospho peptides of NSCLC cells with or without Ephrin B3 
expression were analyzed. First, we demonstrated that ablation of Ephrin B3 expression in 
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NSCLC cells caused a pronounced alteration in cell morphology relative to non-targeting 
siRNA and ceased proliferation. In order to reveal corresponding alterations in the 
phosphoproteome of NSCLC cells with or without siRNA-mediated Ephrin B3 suppression, 
total cell extracts were isolated, lysed after which all cellular proteins were digested into 
peptides. To enable in depth analyses of phosphorylated peptides and reveal relevant 
signaling aberrations on a global scale, we here applied SCX fractionation followed by TiO2-
based magnetic beads capture, the former to reduce sample complexity and the later to 
capture the phosphorylated peptides relative to non-phosphorylated peptides. On the enriched 
phosphorylated peptides in the different fractions obtained from NSCLC cells with or without 
Ephrin B3 siRNA treatment nano-LC and mass spectrometry analysis were applied thereby 
identifying phopsho peptides and corresponding phospho proteins. In total, 1083 unique 
phosphorylated proteins were identified, 150 in Ephrin B3 expressing and 66 in Ephrin B3 
non-expressing NSCLC cells respectively. A much higher number of phospho proteins were 
found in NSCLC cells with intact Ephrin B3 expression which was not surprising as we 
found a pronounced block in proliferation upon Ephrin B3 knockout. 
On the proteins that consistently were found to be differentially phosphorylated in non-
targeted versus Ephrin B3 siRNA treated NSCLC cells, Ingenuity pathway analysis (IPA) 
was used to select candidates for further analyses. In accordance with the pronounced 
alteration in cellular morphology upon Ephrin B3 siRNA, IPA also pointed out networks 
annotated to such cellular functions to be different in Ephrin B3 siRNA expression versus 
non-target siRNA expressing cells. Given that IPA mainly is based on transcription data we 
also applied manual evaluation of the phosphoprotein data using the Protein center 
(PROXEON/Thermo FisherScientific) and the associated information generated for each 
protein by this program. Results from this analysis indicated a putative action mechanism 
where active EphA2 and Focal adhesion kinase 1 (FAK1) were involved in EphrinB3-
mediated cell survival signaling (Figure 6). Thus we found EphA2 to be phosphorylated on 
Ser897 and FAK1 on Ser538 only in NSCLC cells which expressed Ephrin B3. It was 
previously reported that in glioma and prostate cancer cells, EphA2 is phosphorylated on 
Ser897 by Akt1 only in absence of its ligand Ephrin A1 [150]. In line with these findings we 
found that inhibition of Ephrin B3 expression decreased Akt1 Ser129 phosphorylation in 
NSCLC cells. Akt1 Ser129 phosphorylation is reported to be activated by CK2 [195] which 
in turn activate the chaperone HSP90AA1 and rescues EphA2 from proteasome-mediated 
degradation [196] (Figure 6). Indeed analyzing the phosphoproteome of NSCLC cells 
revealed that Ephrin B3 blockade specifically abolished Akt Ser129 phosphorylation and 
HSP90AA1 Ser263 phosphorylation whereas CK2 expression was evident regardless if 
Ephrin B3 expression was blocked. Thus in summary our data suggest a role of Ephrin B3 
and EphA2 in driving NSCLC cell survival signaling. 
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Figure 6: Summary of findings in Paper II.  
4.3 PAPER III 
Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-
small cell lung cancer.  
In Paper III the aim was to analyze Ephrin B3 and EphA2 for their role in controlling 
proliferation, migration and invasion by analyzing in NSCLC cells of different histology in 
vitro and to understand the relevance of Ephrin B3 signaling in vivo using clinical NSCLC 
specimens. In Paper I-II we found Ephrin B3 to be expressed and be of importance for 
proliferation and RT response of NSCLC LC/AC U-1810 cells and here we therefore 
analyzed the expression of Ephrin B3, different Ephs i.e. EphA2, EphA4, EphA3 and EphA5 
but also the EphA2 ligand Ephrin A1 in a panel of NSCLC cell lines of different histology i.e. 
adenocarcinoma (AC), squamous cell carcinoma (SQ) and mixed large cell adenocarcinoma 
carcinoma (LC/AC). Analyses demonstrated that Ephrin B3, EphA2 and EphA3 were 
expressed in the majority of the NSCLC cell lines examined but to various magnitudes and 
with no clear correlation to histology. EphA2 has in NSCLC and other tumor types been 
shown to control proliferation and migration [150] and Ephrin B3 has been reported to 
regulate migration [183]. Here we for the first time demonstrate such an effect of Ephrin B3 
in NSCLC cells by using siRNA. Thus in both AC and LC/AC NSCLC cells Ephrin B3 
reduced proliferation whereas in SQ NSCLC cells no effect was evident. The decrease in 
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proliferation was about the same magnitude as was achieved by a blockade of EphA2 in 
either cell type. 
Importantly by using matrix gel coated transwell assay we found that both endogenous 
Ephrin B3 and EphA2 controlled the invasive potential of NSCLC cells. Moreover, migration 
capacity in AC, LC/AC and SQ NSCLC cells was also reduced to a magnitude similar or 
even more pronounced than was seen upon EphA2 siRNA blockade in the same cells. Eph 
signaling has previously been linked to EMT (epithelial to mesenchymal transition) signaling 
and in particular E-cadherin was demonstrated to influence EphA2 stability [127]. Indeed 
western blot profiling of E-cadherin, and two other EMT regulating proteins vimentin [197] 
and Rac [198] revealed an increase in E-cadherin and vimentin expression while no major 
changes in Rac expression were found in NSCLC cells deprived of either Ephrin B3 or 
EphA2 expression (Figure 7).  
In Paper II we found that Ephrin B3 expression controls EphA2 Ser897 phosphorylation, 
however the putative Ephs by which Ephrin B3 may exerts its effect in NSCLC cells 
remained elusive. In Paper III we therefore applied immunoprecipitation and demonstrate 
for the first time that Ephrin B3 binds EphA2, EphA4, EphA3 and EphA5 in NSCLC cells of 
different histology. Moreover, Ephrin B3 immunoprecipitation revealed that it was in 
complex with EphA2 Ser897 in which also Akt Ser129 and p38MAPK were found, a feature 
observed in all the three NSCLC cell lines examined.  
The expression of Ephrin B3 in NSCLC clinical specimen has not previously been studied 
and given our in vitro analyses of a role of Ephrin B3 in control of NSCLC proliferation, 
migration and invasion we therefore analyzed its expression in a NSCLC patient cohort in 
relation to survival. By immunohistochemistry we demonstrated that Ephrin B3 is 
concomitantly expressed with EphA2 and Ephrin A1 in the majority of the NSCLC clinical 
specimen but in our material neither Ephrin B3 nor EphA2 could be linked to patient survival 
in the cohort as a hole. A higher level of  Ephrin B3 expression was yet found in NSCLC AC 
relative to SQ (P=0.047) but the size of the clinical cohort precluded survival analyses to be 
performed. All in all, we found a novel role of Ephrin B3 in controlling NSCLC cell 
migration/invasion propensity and to be a partner of multiple Ephs in this tumor type. 
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Figure 7: Summary of findings in Paper I-III.  
4.4 PAPER IV 
EphA2 and EphA4 influences DNA Damage Response (DDR) signaling in Non-small cell 
lung cancer and alter radiotherapy sensitivity. 
A recent report showed that EphA5 controlled NSCLC RT response and directly interfered 
with DNA damage response (DDR) signaling via ATM [199]. In Paper IV we therefore 
intended to study if EphA2 and EphA4 influenced basal or RT-induced DDR signaling and if 
this could be used for RT sensitization of NSCLC cells.  
Ephrin B3, Ephrin A1, EphA2 and EphA4 expression were first analyzed in a NSCLC cell 
line panel in relation to their radiation sensitivity measured as Surviving fraction 2 Gray 
(SF2) in clonogenic survival assay. No correlation between SF2 and protein expression levels 
was observed across the entire NSCLC cell line panel however a higher EphA2 expression 
was found in some of the most RT resistant NSCLC cell lines. Nevertheless, we found that 
inhibition of EphA4, Ephrin B3 and to some degree EphA2 expression in such RT resistant 
NSCLC cells decreased proliferation and colony forming potential upon IR.  
By cellular fraction of RT resistant or- sensitive NSCLC cells into membrane and nuclear 
segments and by proximity ligation assay (PLA), the localization of EphA2, EphA4 and 
Ephrin B3 and their interaction with the DDR components pATM (S1981), pDNA-PKcs 
(S2056) and γH2AX (S139) were studied pre- and post IR. In both RT responsive and 
refractory NSCLC cells western blot analysis demonstrated Ephrin B3, EphA2, EphA4 and 
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EphA5 to be expressed in both the membrane and nuclear fractions already prior to IR 
(Figure 8). Accordingly PLA showed EphA2, EphA5 and to some degree EphA4 to interact 
with Ephrin B3 in the nucleus but with no differences pre- and post IR. Importantly, we for 
the first time demonstrated that EphA2, EphA4, and Ephrin B3 interacted with pATM 
(S1981), pDNA-PKcs (S2056) and γH2AX (S139) in NSCLC cells and we observed 
alterations in these interactions upon RT (Figure 8). In line with the previous report on the 
engagement between EphA5 and pATM (S1981) [199], we confirmed this interaction in the 
present study. In conclusion, Paper IV reveals that in addition to Ephrin B3, EphA2 and 
EphA4 are likely also molecular targets that can be used for RT sensitization of NSCLC cells. 
Moreover, our data thus suggests that interfering with these targets may beyond influencing 
RT-induced cell death propensity and cell cycle progression (Paper I) also intervene with 
DDR as part of their action mechanism.   
 
Figure 8: Summary of findings in Paper IV.  
4.5 EPHRIN AND EPH SIGNALING IN NSCLC: LESSONS LEARNED IN 
CONTEXT OF CURRENT KNOWLEDGE OF THE FIELD  
In Paper I, Ephrin B3 was identified as a RT sensitizing target in NSCLC and in Paper IV 
also EphA2 and EphA4 were identified as molecular switches that enable RT sensitization in 
NSCLC cells. Ephrin B3 was in Paper I demonstrated to control proliferation, cell cycle 
progression and to protect from RT-induced cell death via multiple routes. Results from 
Paper IV indicated that in addition to Ephrin B3 also EphA2 and EphA4 also intervened 
with DNA damage response (DDR). Interestingly, our results of EphA2 and EphA4 as RT 
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sensitizing targets are novel but in line with the report on EphA5 by Staquinici et al. who 
described EphA5 as a RT response modulator in NSCLC cells by interacting with the DDR 
component ATM [199].  
The interest of targeting EphA2 which is overexpressed in various tumors has emerged and 
multiple strategies for such targeting have been described. This therapeutic avenue on EphA2 
is further emphasized since we in this thesis show that EphA2 also interact with DDR 
signaling upon RT.  
The interconnection between growth factor receptors and DDR signaling is most well 
characterized for EGFR and IGF-1R [200, 201]. Thus both EGFR and IGF-1R are reported to 
interact with DNA-PK when cells are subjected to RT [87, 202, 203]. RT not only activates 
DNA repair but also EGFR [202, 203] and IGF-1R [87] which subsequently impacts ERK 
and Akt signaling and as a result IR-mediated apoptosis is inhibited. Moreover, EGFR 
triggered Akt has been shown to directly control DNA-PKcs phosphorylation at Ser2056 and 
Thr2609 the later which in turn regulated Akt phosphorylation [201].  
Since Ephrin B3 and EphA2/EphA4 similar to EGFR and IGF-1R in Paper IV were found to 
intervene with DDR signaling and given that we found that EphA2 ablation per se and as a 
consequence of Ephrin B3 inhibition results in altered Akt phosphorylation (Paper I-III), it 
would be interesting to further elucidate if the phosphorylated Akt that we found in EphA2 
immunocomplexes in NSCLC cells (Paper III) may in fact control phosphorylation of DNA-
PKcs or other DDR components.  
Blocking EGFR signaling has indeed been shown to sensitize tumor cells to RT as illustrated 
in cells with K-RAS mutation where a decreased DNA-repair and increased RT sensitivity 
upon pharmacological EGFR blockade was reported [204]. With respect to results in Paper 
IV it would therefore also be of interest to study the effect on EphA2 when blocking EGFR 
and PI3K signaling upon RT since additional blockage of EphA2 using for example a small 
kinase inhibitor could give rise to an even more pronounced sensitivity to RT in NSCLC 
cells. In addition to EphA2 it would be relevant to study if Ephrin A1 administration or 
blocking Ephrin B3 interaction with Ephs would be an even more potent way in context of 
EGFR blockade since both such strategies may directly target several Ephs or indirectly 
influence other RTKs such as IGF-1R.  
DNA DSBs formation as a result of oncogenic stress have been associated with induction of 
senescence and reported to be suppressed upon ATM inhibition in a mouse tumor model 
resulting in increased invasiveness [205]. In Paper I we showed that inhibition of Ephrin B3 
in combination with IR resulted in increased senescence cells and cellular arrest in G0/G1-
phase of the cell cycle. Moreover, in Paper IV Ephrin B3 was shown to interact with pATM 
(S1981) and we found that this interaction increased after RT. Thus it would be interesting to 
analyze if forced overexpression of Ephrin B3 and/or EphA2/EphA4 also would lead to a 
decrease in pATM (S1981) and reduced senescence in RT-sensitive NSCLC as such evidence 
would strengthen the case of Ephrin B3/EphA2/EphA4 as RT sensitizing targets.   
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EphA2 has been shown to exert ligand-independent pro-oncogenic functions as a result of 
reduced EphrinA1 ligand expression and altered Akt activation [151]. Accordingly 
administration of Ephrin A1 has been reported to decrease invasiveness and tumorigenic 
potential [206, 207]. Moreover, EphA2 has been reported to be a substrate of Akt in different 
tumor forms including glioma and prostate cancer [150, 156]. Hence, in glioma cells addition 
of exogenous Ephrin A1 was reported to block EphA2 Ser897 and Akt Ser129 
phosphorylation and impair migration and invasion [150]. In line with these reports we in 
Paper II we found EphA2 to be phosphorylated on Ser897 and Akt on Ser 129 only when 
Ephrin B3 expression was maintained in NSCLC cells indicating that Ephrin B3 engagement 
with EphA2 might trigger another signaling than those elicited upon Ephrin A1 binding. 
Moreover, treatment with exogenous Ephrin A1 was found to decrease phosphorylation of 
FAK and prevent cell migration [208] hence further supporting another function of Ephrin B3 
with respect to EphA2. 
Akt1 Ser129 phosphorylation was furthermore reported to be regulated by CK2 in Jurkat 
cells [195] and in turn activate the chaperone HSP90 [209] prohibiting EphA2 from 
proteasome- mediated degradation [196]. In Paper II we indeed showed that HSP90AA1 
Ser263 phosphorylation was evident only in NSCLC with intact Ephrin B3 expression 
illustrating that such mechanism with respect to EphA2 may also exist in NSCLC cells.  
In Paper III we found that Ephrin B3 is a ligand of EphA2 and reported that inhibition of 
either Ephrin B3 or EphA2 decreased proliferation, migration and invasion as well as EMT 
signaling in NSCLC cells. Moreover, we demonstrate that Ephrin B3 is concomitantly 
expressed with Ephrin A1 and EphA2 in both NSCLC cells in vitro and also in NSCLC 
clinical material. We may from our data speculate that Ephrin B3 binding is more potent 
when it comes to activation of the EphA2 receptor and therefore the inhibitory action of 
Ephrin A1 that previously has been described [150] will be circumvented.  
Notably, the Ephs has in general different functions in different tumor types and the site of 
EphA2 seems to matter. In both prostate- and breast cancer EphA2 phosphorylation is 
necessary to for the oncogenic potential of EphA2 [157-159] whereas other studies state that 
EphA2 phosphorylation causes tumor suppression [161] or that EphA2 phosphorylation is not 
needed to cause kinase activity and tumorigenic potential [128, 160]. Moreover, it has been 
shown that binding of Ephrin A1 to EphA2 results in tyrosine phosphorylation and EphA2 
downregulation [131], thus acting as a tumor suppressor. Given the findings from Paper II 
further analysis of EphA2 phosphorylation on particular sites should be carried out in 
NSCLC cells with either Ephrin A1 or Ephrin B3 binding in order to understand their role in 
NSCLC cell signaling.  
Our data generate a hypothesis of alternative binding or engagement with the EphAs than 
used by Ephrin A1 as the opposite effects on cellular signaling is apparent. It has been shown 
that in addition to the normal forward signaling and Ephrin binding to Eph in trans at the 
same time another Ephrin can bind to the same Eph in cis [130]. This novel reports generates 
an expansion of our hypothesis that Ephrin B3 may in contrast to Ephrin A1 bind EphA2 in 
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both cis and trans thereby enabling a different cellular signaling pattern. One may speculate 
that Ephrin B3 binding is more potent than Ephrin A1 engagement and therefore the 
inhibitory action of Ephrin A1 that previously has been described [150] will be circumvented 
by Ephrin B3 binding resulting in activation of EphA2. Further studies on Ephrin B3 
engagement with EphA2 using surface plasmon resonance (SPR) are therefore warranted.  
In Paper III we found EphA2 to bind p38MAPK which has indeed been shown to be in 
complex with IGF-1R thereby acting as a pro-survival factor and a blocker of RT- induced 
cell death [87]. Hence, EphA2 also might when bound to Ephrin B3 exert pro-survival 
signaling via this route and given our findings in Paper IV where also EphA2 blockade was 
found to cause RT sensitization, our data may also suggest such a route of signaling to control 
NSCLC RT sensitivity. It would indeed therefore be interesting to analyze how the EphA2 
complex looks like in RT sensitive NSCLC cells and to what extent they have active 
p38MAPK upon RT.  
In Paper III we demonstrate that Ephrin B3 also bind EphA3, EphA4 and EphA5. The role 
of EphA3 in NSCLC proliferation or migration has not been analyzed whereas inhibition of 
EphA4 was reported to promote migration [132] and suppression of EphA5 to block cell 
survival in NSCLC [199]. The results on EphA5 as a driver of proliferation and a RT 
sensitizing target is in line with our findings on EphA2 presented in Paper III-IV. EphA4 is 
a dependence-receptor and in absence of its ligand Ephrin B3, EphA4 is cleaved and 
subsequently undergoes apoptosis [210]. It has been demonstrated that EphA4 mRNA 
expression is, in contrast to EphA2, associated with improved outcome in NSCLC [132]. 
Moreover, in vitro studies have shown that overexpression of EphA4 in NSCLC cells with 
low endogenous EphA4 expression decreases ERK expression and inhibits migration and 
invasion [132]. These results are somewhat in contrast to our results which demonstrate 
Ephrin B3 to be a ligand of EphA4 and given that we found that a blockade of EphA4 
expression sensitized NSCLC cells to RT. As we did not studied the role of EphA4 with 
respect to migration in our system we cannot rule out that it is a cell type dependent effect in 
which the expression of other Ephrin ligands may play a role. 
In NSCLC patient samples, EphA2 expression was positively associated with a smoking 
history and a high EphA2 score predicted poorer overall- and progression-free survival of 
NSCLC patients [145, 146]. EphA2 also showed correlation to activated EGFR where a 
higher level of expression was observed in tumors with K-RAS mutations [145]. In our 
patient material AC displayed higher levels of Ephrin B3 compared to SQ and with respect to 
EphA2 there was a tendency of higher expression in AC. As for Ephrin A1 the expression 
was high both in AC and in SQ. We did not in contrast to Brannan et al., [145] found that 
EphA2 was linked to poorer outcome. Our analyses of Ephrin B3 and EphA2 in NSCLC in 
Paper III show that it is important to analyze different histological subtypes of NSCLC 
separately and then use bigger patient material to allow for subgroup analyses with respect to 
patient survival and prognostic potential. It would also be interesting to perform profiling of 
different Eph and Ephrin ratios in the NSCLC specimen to further understand their potential 
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as prognostic biomarkers in NSCLC. To get a bigger picture more parameters than patient 
survival should also be looked upon such as smoking history but also EGFR/K-RAS mutation 
status or IGF-1R expression as these all have been shown to influence EphA2 signaling [108, 
145, 146]. As our in vitro data from NSCLC indicate that both Ephrin A1 and Ephrin B3 may 
compete for the same EphA2, and given that Ephrin B3 engagement results in EphA2 Ser897 
phosphorylation, it would be of further value to study the Ephrin and Eph interaction in situ 
in NSCLC by using PLA. Finally, it will also be of importance to look into the different 
regions of the tumor specimen and sort out what Ephrins and Ephs operate in different rumor 
parts due to the tumor heterogeneity. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
In this thesis I put evidence that Ephrin B3 alongside different Ephs control NSCLC cell 
proliferation, migration, invasion and RT response. I here would like to make some outlook 
on my findings in context of biomarkers and therapeutic avenues for NSCLC and other tumor 
types.  
In NSCLC adenocarcinoma small molecules against EGFR mutations or towards the EML4-
ALK fusion protein has resulted in a new era of precision cancer medicine strategies. 
However there are still some challenges such as the fact that these genetic aberrations of 
NSCLC are only found in 1-5% of all NSCLC cases and development of drug-resistance 
associated mutations or signaling aberrations constitute clinical problem [211, 212]. Despite 
the fact that new agents are being tested in clinic against the acquired EGFR resistance, there 
is expected that patients will eventually also develop acquired resistance to these agents 
[211]. Hence, there is a need to identify additional targets and novel ways to combat signaling 
aberrations of NSCLC and here I present some evidence of Ephrin B3 and associated Ephs in 
this respect.   
In the constituting papers of my thesis it is demonstrated that Ephrin B3 and multiple Ephs 
control NSCLC proliferation, migration, invasion and response to RT illustrating that 
targeting Ephrin B3 for therapeutic purposes in NSCLC may hold potential alone or in 
combination with RT. As we in Paper I and Paper III found that ablation of Ephrin B3 or 
EphA2 expression decreased MAPK ERK, p38MAPK and Akt signaling, one may speculate 
that Ephrin B3 signaling via EphA2 or other Ephs are drivers of these pathways instrumental 
for controlling proliferation and invasion. Given that EphA2 and EGFR show functional 
interaction [208] and given that EGFR is known to control the MAPK/Akt signaling, such 
alternative pathway via Ephrin B3 and associated Ephs may drive resistance to treatment in 
EGFR mutated NSCLC cases. There are indeed multiple reports that support a role of EphA2 
in erlotinib and gefitinib treatment response of NSCLC while a role of Ephrin B3 still 
remains to be established albeit our findings of their interaction point in such direction. Thus 
EphA2 has been found to be overexpressed in gefitinib resistant NSCLC cells and inhibition 
of EphA2 expression or treatment of such NSCLC cells with the multikinase inhibitor 
dasatinib, restored the sensitivity to gefitinib [208]. Moreover, Brannan et al., also showed 
that erlotinib treatment of responsive EGFR-mutant NSCLC cell lines decreased EphA2 
expression [145, 146] and Koch et al., by phospho proteomic profiling demonstrated that 
EphA2 may drive EGFR resistance in vitro [208]. Recently an increased EphA2 expression 
level was reported in NSCLC upon erlotinib resistance [213, 214].  Thus targeting EphA2 by 
using a small molecule against the EphA2 kinase domain was reported to revert erlotinib 
resistance in vivo in mice causing a decreased EphA2 expression level [213]. However as 
EphA2 expression is reported to correlate with EGFR expression [145] targeting aberrant 
Ephrin B3 or EphA2 signaling will likely be a therapy that goes beyond EGFR-mutation 
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driven NSCLC. Based on our results showing that Ephrin B3 binds to multiple Ephs enabling 
migration and proliferation potential I propose that targeting the interaction of Ephrin B3 with 
Ephs would be more efficient than ablating EphA2 kinase as signaling through multiple 
receptors then could be blocked and the problem of poor kinase inhibitor selectively could be 
circumvented.  
Current therapeutic strategies for EphA2 aims to target kinase signaling by mimicking Ephrin 
A1 ligand engagement using either small molecules, agonistic antibodies or by application of 
kinase inhibitors towards EphA2 kinase domain [108, 151, 213]. Indeed doxazosin, a small 
molecule agonist for EphA2 and EphA4 which act in a similar way as Ephrin A1, inhibit Akt 
and ERK kinase activities in an EphA2-dependent manner, resulting in EphA2 internalization 
and suppressed migration of prostate cancer, glioma cells and breast cancer [151]. However 
since tyrosine kinase inhibitors usually have poor specificity and since in the most cases 
Ephrin A1 ligand-dependent stimulation of Eph kinase activity is tumor suppressive, both 
these approaches may not be efficient [215]. Here targeting Ephrin B3 and EphA interaction 
may be a more promising strategy as we found this signaling to be pro-proliferative and to 
influence migration and invasion potential and also to go beyond EphA2 into other EphA 
receptors.  
Deregulated EphA2 is reported in multiple tumor types and evidences indicate that targeting 
EphA2 signaling either alone or in combination with other agents may have a role in other 
tumor types than NSCLC. Thus EphA2 expression has been correlated to reduced overall 
survival in breast cancer [216] and inhibition of EphA2 was reported to restore sensitivity to 
trastuzumab [217]. Moreover, targeting of EphA2 in combination with the ER estrogen 
receptor α in breast cancer was reported to restore tamoxifen sensitivity [218]. In melanoma, 
EphA2 has been reported to be a mediator of vemurafenib resistance [219] and in colorectal 
cancer high EphA2 expression has been correlated with worse outcome in patients treated 
with cetuximab [220]. Given our findings of Ephrin B3 as an interactor of EphA2 it would be 
interesting to further explore as to what extent Ephrin B3 also could be used as a target for 
therapy in all these malignancies per se and in the context of other targeted therapies.  
With respect to my findings on Ephrin B3 it would be highly interesting also to explore it for 
imaging purposes in PET (Positron Emission Tomography) imaging as a way to follow 
metastatic NSCLC and its response to therapy, such as RT. This is of particular interest since 
my work show Ephrin B3 and two of its interacting receptors EphA2 and EphA4 to 
contribute to RT resistance of NSCLC. PET labelled EphA2 antibody has been successfully 
used in monitoring breast cancer tumor growth [221], and PET labelled EphA5 was 
successfully described to monitor NSCLC growth, and to some extent RT response [199]. In 
our NSCLC panel I have shown that in contrast to Ephrin B3, the cells do not express all 
Ephs, and Ephrin B3 binds to several Ephs. Thus, the development of an Ephrin B3-directed 
PET labelled antibody could be interesting for observing RT response in NSCLC patients. 
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In conclusion, in this thesis I have put forward evidence that Ephrin B3 and its associated 
Ephs may offer a novel way to combat NSCLC and may be candidates for future precision or 
personalized therapy approach of this tumor malignancy. 
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